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This paper describes a fast and direct method for quantification of arginine and ascorbic acid (vitamin C) in effervescent 
tablets. HPLC-UV multidimensional chromatography (RP18 and cyanopropyl columns) was developed and validated. 
Phosphate buffer 10 mM pH 3.4 was used as mobile phase. Satisfactory resolution between the drugs was obtained with 
analysis time less than 8.0 min. Method was linear in the ranges of 140-320 g.mL-1 and 240-560 g.mL-1 for arginine and 
ascorbic acid, respectively. Precision showed RSD <2.0%. Recovery was 99.5% and 100.0% for arginine and ascorbic 
acid, respectively. Robustness was confirmed through factorial analysis 22 (pH and mobile phase flow rate as factors). 
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Introduction 
L-arginine is a basic and hydrophilic amino 
acid classified as a conditionally essential 
amino acid and in humans is synthesized from 
citrulline (1). Arginine (ARG) plays an 
important role in protein synthesis and increase 
muscle endurance by delaying the occurrence 
of peripheral fatigue. ARG is the immediate 
precursor of nitric oxide (NO), urea, ornithine 
and agmatine and is necessary for the synthesis 
of creatine. As a precursor of NO, arginine is 
used in many conditions where vasodilatation is 
required. It can also be used for the synthesis of 
polyamines (mainly through ornithine and to a 
lesser degree through agmatine, citrulline, and 
glutamate). Moreover, it is a precursor of 
proline and hydroxyproline, which are 
substances necessary for the synthesis of 
connective tissue (2,3). 
Ascorbic acid (AA) is a water soluble 
vitamin essential to humans. It is part of a group 
of chemicals complex necessary for the proper 
functioning of the body and its deficiency may 
be caused by an unbalanced diet. AA is 
important in metabolic processes such as 
synthesis of collagen, so vital for the repair and 
healing of connective tissue (4), and synthesis 
of norepinephrine (5) and steroids (6). In 
addition, it acts on the immune system and also 
as an antioxidant neutralizing free radicals and 
oxidants (7). 
Analysis of ARG by reverse phase (RP) 
HPLC is commonly carried out by pre-column 
derivatization. This process is commonly used 
to reduce ARG polarity, improving the 
interaction with the RP column, and also 
increases the wavelength of detection. Studies 
employing o-phthaldialdehyde (8,9) and phenyl 
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isothiocyanate (10) for derivatization showed 
good results for analysis of ARG and 
metabolites. The sensitivity and selectivity of 
the mass detector were explored for the direct 
analysis of ARG and metabolites (11,12,13). 
Few studies are described with direct analysis 
of arginine by HPLC-UV detection. In this 
context can be cited the separation of arginine, 
ibuprofen and its impurities with detection at 
264 nm (with bandwidth of 100 nm to achieve 
the detection of ARG at wavelength around 210 
nm) (14). HPLC methods for AA employing 
electrochemical (15,16) and UV (17,18) 
detection are described for synthetic and 
biological samples. 
Multidimensional chromatography employs 
two columns in sequence with different 
chromatographic selectivities. HPLC 
multidimensional methods are used to increase 
the resolution between substances in analysis of 
complex mixtures. Its advantageous is the 
direct analysis, in isocratic mode, of samples 
which commonly needed to be derivatized or 
require gradient system (19,20).    
The combination of arginine and ascorbic 
acid in effervescent tablets is indicated for 
cicatrization, as antioxidant, to improve the 
immune system and in restrictive or inadequate 
diets, when there is vitamin C deficiency. In our 
searches, we have found no method for 
quantifying arginine and ascorbic acid in 
pharmaceutical formulations. The present work 
aims to develop and validate a direct and fast 
multidimensional HPLC-UV method for 
determination of ARG and AA in effervescent 
tablets.  
 
Experimental 
AA standard was purchased from MBN 
Chemicals Ltd.® with purity of 99.81% and 
arginine aspartate standard from Zhejiang 
Medicines and Health Products Imp. Ex® with 
purity of 99.23%. The concentration of arginine 
aspartate in the standard solutions was 
multiplied by the factor 0.567 to obtain the 
concentration of ARG. This factor was 
calculated by the ratio of ARG molecular 
weight (174.2 g.mol-1) by arginine aspartate 
(307.3 g.mol-1). Sodium phosphate dibasic 
anhydrous (Bold®), phosphoric acid (Vetec®) 
EDTA (Vetec®) and ultra-purified water from 
purification unit (RF Easypure®). Biofor C® 
effervescent tablets containing 1.0 g of ascorbic 
acid, 1.0 g of arginine aspartate and as inactive 
ingredients: citric acid, flavor solid with 
guarana açai, aspartame, sodium bicarbonate, 
colloidal silicon dioxide, colorant yellow, 
maltodextrin and mineral oil.  
Chromatographic system consisted of a 
HPLC Merck Hitachi - Lachrom®, diode array 
detector and HSM software Multi-Manager®. 
Columns ACE® RP-18 (250 mm x 4 mm, 5 μm) 
and Spherisorb® cyanopropyl (250 mm x 4.6 
mm, 5 μm). Sample filtration through Millex 
Millipore® membrane (nylon, 0.45 μm).  
 
Sample Preparation 
All samples (ARG and AA) were dissolved 
and diluted with sodium phosphate dibasic 10 
mM adjusted to pH 3.4 with phosphoric acid 
and EDTA 0.005%, diluent solution. EDTA 
was added to chelate metal ions and minimize 
the degradation of ascorbic acid in solution. The 
volumetric flasks were protected from light 
with aluminum foil to prevent degradation of 
ascorbic acid. 
The standard stock solutions (SSS) were 
prepared by weighing 50 mg of arginine 
aspartate, or 50 mg of AA in 25 mL volumetric 
flask, diluting to obtain concentrations of 1.15 
and 2.00 mg.mL-1 for arginine and ascorbic 
acid, respectively. From these SSS were made 
dilutions to obtain the concentrations for 
validation test. 
 
Analytical Method Development 
Variations in chromatographic conditions 
including composition (acetonitrile, methanol 
and aqueous phases), pH (2.5 – 7.0) and flow 
rate (0.6 – 1.2 mL.min-1)of the mobile phase, 
and different columns (C18 and Cyanopropyl) 
were carried out to best fit the quantification of 
ARG and AA.  
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Validation Tests 
The chromatographic conditions employed 
for the quantification of ARG and AA are 
described in Table 1. The validation process 
used the ICH guides as a reference (21). 
 
Table 1. Chromatographic conditions for the quantification of arginine and 
ascorbic acid by multidimensional HPLC-UV. 
HPLC 
Variables Description 
Mobile Phase 10 mM phosphate buffer pH 3.4 
Column 
Sequence 
ACE® C18 (250 x 4 mm, 5 m) and Spherisorb® 
ciano-propil - 5CN (250 x 4.6 mm, 5 m) 
Injection 
Volume 
20  L 
Flow rate 1.0 mL/min 
Oven 
Temperature 
30 °C 
Detection 205 nm (bandwidth 8 nm) 
Run time 
analysis 
7.5 min 
 
Specificity 
Chromatograms from tablet samples (at 
concentration of 100%) were compared with 
placebo solution. Placebo solution was 
prepared by weighing a mixture of excipients of 
the effervescent tablets (anhydrous citric acid, 
baking soda, aspartame, maltodextrin, colloidal 
silicon dioxide, mineral oil, fragrance and dye) 
in volumetric flask of 25 mL using diluent as 
solvent. This solution was diluted to obtain 
placebo solution similar to those observed in 
the effervescent tablets.  
For peak purity analysis, spectra in the range 
of 200–300 nm were recorded at a frequency of 
0.5 Hz and noise set from 0.2 – 1.0 min. No 
detected impurity was considered when the 
peak purity index was greater than 0.995 and 
the threshold curve did not intercept the 
similarity curve. 
 
 
Linearity 
Linearity of the method was demonstrated 
through the construction of curves in the range 
of 60 – 140% (140-320 and 240-560 μg.mL-1 
for ARG and AA, respectively). For each curve 
were prepared five different concentrations (60, 
80, 100, 120 and 140%), each one in triplicate 
in a total of 15 points (peak area vs 
concentration) per curve.   
 
Precision 
The method precision was evaluated by, 
repeatability and intermediate precision. 
Repeatability was determined by seven 
determinations at 100% of test concentration 
(230 and 400 μg.mL-1 for ARG and AA, 
respectively) in duplicate. The test solutions 
were prepared from the triturated effervescent 
tablets which were weighted and diluted to 
working concentration. For each day of 
repeatability were prepared two standard 
solutions containing the drugs at a 
concentration of 100%. The intermediate 
precision was determined by analyzing the 
repeatability of the method on different days.  
 
Accuracy 
Solutions containing ARG and AA 
contaminated with placebo were prepared to 
access method accuracy. Five concentrations 
were used, covering the range of the test (60, 
80, 100, 120 and 140%) for both drugs (ARG 
and AA). Each concentration was performed in 
duplicate. For calculation of recovery two 
standards containing only ARG and AA were 
prepared at 100% of test concentration. 
 
Robustness 
Robustness was evaluated by deliberate 
variations in pH and flow of mobile phase. The 
effect of factors (pH and flow) in the 
quantification of drugs and the 
chromatographic parameters (resolution, peak 
asymmetry, retention time and column 
efficiency) were evaluated by factorial design 
22. Flow rate levels tested were 0.90 and 1.05 
mL.min-1, and pH 3.2 and 3.6. Analysis on the 
nominal level of the method (pH 3.4 and flow 
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of 1.00 mL.min-1) was performed to compare 
the results. 
 
Results and Discussion 
To obtain a chromatographic method for 
quantification of ARG and AA initially was 
tested reversed phase C18 columns (RP18), 
commonly used in drug analysis. ARG is 
positively charged (pKa = 13.2) across the pH 
range commonly used in HPLC (pH 2.0 – 8.5) 
which reduces the affinity of the drug by RP18 
column. To increase the affinity of ARG was 
added sodium dodecyl sulfate (SDS 0.2%) on 
mobile phase as ion pair. This approach 
increase the retention time of ARG, but was not 
succeeded in separating the drugs under 
analysis (Figure 1.a).  
 
Figure 1. Chromatograms of arginine (ARG) and ascorbic acid (AA) obtained 
during the method development. a) Phase reverse C18 (RP18) column using SDS 
as ion pair; b) Cyanopropyl column using pentane sulfonate as ion pair.   
 
 
 
Due to the high polarity and water solubility 
of AA and ARG, were carried out assay with 
polar cyanopropyl column using phosphate 
buffer pH 3.4 as mobile phase. Pentane 
sulfonate (0.2%) was added to mobile phase, as 
ion pair, resulting in satisfactory resolution 
between the drugs and placebo (Figure 1.b). 
However, the diluent showed relevant signal at 
the same retention time of ARG. The influence 
of the diluent under these conditions was 
confirmed with peak purity value < 0.9 and high 
value of the intercept (8.5%) in a study of 
linearity with the ARG standard (Figure 2). The 
values of percentage intercept calculated by 
equation 1 must be lower than the specification 
established for precision (relative standard 
deviation - RSD < 2.0%, in this case), 
demonstrating that the method variation/error 
explain the intercept dimension obtained in the 
linearity test (22). 
%𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =
𝑎
𝑏×?̅?
  Equation 1 
Where a is the intercept; b is the slope; ?̅? is the 
mean concentration. 
 
Figure 2. Linearity plot of arginine using different columns (CN - cyanopropyl 
column, and multidimensional chromatography – RP18 + cyanopropyl columns 
in sequence). In bold the results of intercept percentage calculated by equation 1. 
CN data were normalized dividing it by the sum of multidimensional 
chromatography area. 
 
 
 
 
 
 
 
 
 
 
 
Satisfactory results for the resolution of the 
drugs peaks, placebo and diluent were obtained 
using the columns RP18 and cyanopropyl in 
sequence (multidimensional chromatography) 
(Figure 3). Using this method there was no need 
of adding substances to ion pairing. Under these 
conditions it was possible to validate the 
method for quantification of ARG and AA as 
demonstrated by the results and discussions 
described below. 
 
Specificity 
In general, the use of wavelengths below 210 
nm is avoided, basically for two reasons: the 
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emission of the deuterium lamp is lower in this 
band (signal/noise ratio is high and sensitivity 
low) and many interferers absorb in this region 
(potential specificity problem). At 205 nm 
ARG and AA (maximum and minimum 
wavelength, respectively) have similar 
absorptivities. As the working concentrations 
were not close to the limit of quantification and 
the placebo did not interfere with the analysis 
(as will prove the results of validation), the 
wavelength of 205 nm was selected for the 
ARG and AA quantifications. 
There was no peak detected for placebo at 
the retention time corresponding to the 
chromatographic peaks of ARG and AA 
(Figure 3). Peak purity analysis does not 
detected impurities on the peaks of ARG and 
AA and the peak purity index was higher than 
0.999 for both drugs. Retention times of ARG 
and AA were 6.30 and 6.95 min, respectively. 
The inversion in the order of elution of the 
drugs in the multidimensional chromatography 
method with respect to the methods of Figure 1 
can be justified by the absence of ionic pair 
agent that alters the interaction of drugs with the 
columns. 
 
Figure 3. Chromatograms of the Biofor C effervescent tablets and placebo at 205 
nm with the columns RP-18 and cyanopropyl in sequence (multidimensional 
chromatography). Concentrations of 230 and 400 μg.mL-1 for arginine (ARG) and 
ascorbic acid (AA), respectively. 
 
Linearity 
The linear regression lines were obtained 
plotting the peak area at 205 nm (in mAu.s) 
versus the concentration of ARG or AA (in 
μg.mL-1). The summary of results are in Table 
2. The higher slope obtained with the results of 
AA compared to ARG shows a greater 
sensitivity of the method for detection of AA. 
The coefficients of determination (r2) close to 
1.00 show that virtually all the variation on the 
peak areas can be explained by variations in the 
concentrations of the drugs. The standardized 
residuals in the range of -2.0 to 2.0 shows that 
there were no outliers for peak area in the 
experimental data. Residual graphics showed 
normal distribution of results without the 
presence of trends, demonstrating that the 
model of first order, without transformation of 
data, is adequate to describe the relationship 
between peak area and concentration of the 
drugs. The ratio of the standard error of 
regression (SER) and the mean peak area 
obtained by the linear regression equation can 
be considered a measure of dispersion of the 
results of linearity (Equation 2), and 
comparable to the calculated RSD of the 
precision results. The low values of RSDreg 
show that the method has adequate precision 
and were compatible with the technique and 
sample (tablets) analyzed (22) 
%100


Xb
SER
RSDreg  Equation 2 
Where: RSDreg = relative standard deviation of 
the regression in %; SER = standard error of 
regression, b = the regression slope, X = 
average concentration of the samples in the 
calibration curve. 
 
Table 2. Summary of linearity results. 
Linearity Arginine Ascorbic Acid 
Concentration Range 
(µg/mL) 140 - 320 240 - 560 
Equation y = 7251x + 33304 y = 10903x + 83049 
Determination 
Coefficient (r2) 0.9993 0.9998 
Standadized 
Residuals (Extreme 
Values) -1.44 , +1.33 -1.20 , +1.13 
Residuals Plot No tendency No tendency 
Regression Precision 1.0% 0.5% 
Percentage Intercept 2.0% 1.8% 
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Precision 
There is additive variance between the levels 
of precision and the highest variability is 
expected for the intermediate precision which 
includes the variations of system precision and 
repeatability. For samples at the same level of 
concentration is possible to calculate the system 
precision, from injections in duplicate, using 
Equation 3 (23). 
%100
2
)( 221




x
k
xx
RSD
ii
Inj  Equation 
3 
Where: RSDInj is the HPLC system precision, 
in %; xi1 and xi2 are the peak areas of different 
injections of the sample i; k is the number of 
samples; x  is the average peak area of the 
samples. 
Repeatability was evaluated by calculating 
the RSD (RSDRep) from the results of different 
samples in each day of precision assay. The 
intermediate precision was obtained by 
measuring the variability (RSDInt) of pooled 
results from different days of precision. Table 3 
summarizes the results. Low values of RSD (< 
2.0%) evaluated at all levels show that the 
method is precise. 
During the precision assay has been verified 
that the sample solutions containing the drugs 
were stable for at least 12 h. 
 
Table 3. Summary of results from different levels of precision for effervescent 
tablets. 
Precision 
Arginine  Ascorbic acid 
Day 1 Day 2  Day 1 Day 2 
Injection precision - RSDInj 
(%) 
0.41 0.54  0.43 0.36 
Repeatability - RSDRep (%) 1.64 1.41  1.04 1.12 
Intermediate precision –
RSDInt (%) and (Dose) 
1.57 (102.4%)  1.37 (97.0%) 
 
 
 
Accuracy 
Recoveries of the drugs in the samples 
contaminated with placebo were 99.5% and 
100.0% for ARG and AA, respectively. 
Variability of results was low with values of 
RSD for the ten samples, equal to 1.82% and 
1.11% for ARG and AA, respectively. These 
results confirm the specificity, accuracy and 
precision of the analytical method proposed. 
 
Robustness  
An analytical method for use in routine 
should be able to withstand small variations 
without changing significantly the 
quantification of drugs. The proposed method 
is robust to variations on the factors pH and 
flow showing low variability (Table 4). 
 
 
 
The transfer of analytical methods between 
laboratories often requires adaptations to adjust 
the chromatographic parameters (resolution, 
asymmetry, retention time). Thus, the analysis 
of the results of deliberate variations in method 
indicates that the pH 3.6 improves the 
resolution between peaks; the retention time 
increases with pH 3.2; the asymmetry of the 
peak of ARG is better at pH 3.2, while AA is at 
pH 3.6. The analysis with similar columns 
under the same conditions that was proposed in 
this study showed low resolution between ARG 
and AA. This problem was easily solved by 
reducing the flow to 0.8 mL.min-1 and 
increasing pH to 3.6. 
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Conclusions 
 
The use of multidimensional 
chromatography was effective to separate and 
quantify ARG and AA from effervescent 
tablets and there is no need for pre-column 
derivatization. The intercept from linear 
regression was able to detect a quantitative 
influence of the diluent in the analysis of ARG 
during the development phase of the HPLC 
method leading us to the use of 
multidimensional chromatography. 
Satisfactory results for specificity, linearity, 
precision, accuracy and robustness validate the 
method for analysis of effervescent tablets 
containing ARG and AA by multidimensional 
HPLC-UV. 
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